Refining ICI-based treatment selection in metastatic clear cell RCC
Автор: VJOncology
Загружено: 2025-11-27
Просмотров: 11
Berkay Simsek, MD, Brigham and Women's Hospital, Boston, MA, comments on the various biomarkers being studied in metastatic clear cell renal cell carcinoma (mccRCC), including circulating and tissue-based biomarkers. With the advent of tools like spatial transcriptomics and high-resolution single-cell RNA sequencing, selecting patients for immune checkpoint inhibitor (ICI) therapy will be optimized. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: